Consensus Bio-Techne Corporation

Equities

TECH

US09073M1045

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-03 pm EDT			5-day change	1st Jan Change
77.29 ^USD	+2.24%		+20.65%	+0.17%

May. 02	UBS Adjusts Price Target on Bio-Techne to $90 From $80, Maintains Buy Rating	MT
May. 02	Leerink Partners Adjusts Price Target on Bio-Techne to $95 From $85	MT

Evolution of the average Target Price on Bio-Techne Corporation

Price target over the last 5 years

History of analyst recommendation changes

db2c8d6477.aZ_qlDM6hFzm_IVkwiP_32a6o7JsvXyhCTVfF9sTA5k.B_mO0QRo7yrfjOkhjHvSqwDq18Ao1znEaEZpdZVEceAZ0bnSVQzOHoOP9g~2183b111b7358defa95cb69bbf5a06d3

Analyst Recommendations on Bio-Techne Corporation

UBS Adjusts Price Target on Bio-Techne to $90 From $80, Maintains Buy Rating	May. 02	MT
Leerink Partners Adjusts Price Target on Bio-Techne to $95 From $85	May. 02	MT
Scotiabank Adjusts Price Target on Bio-Techne to $83 From $80	May. 02	MT
RBC Capital Adjusts Price Target on Bio-Techne to $72 From $71, Sector Perform Rating Kept	May. 02	MT
Baird Adjusts Bio-Techne Price Target to $81 From $73	May. 02	MT
Deutsche Bank Adjusts Price Target on Bio-Techne to $84 From $82	May. 01	MT
RBC Capital Adjusts Price Target on Bio-Techne to $71 From $79	Apr. 29	MT
Deutsche Bank Adjusts Bio-Techne Price Target to $82 From $85	Apr. 18	MT
RBC Raises Price Target on Bio-Techne to $79 From $75, Keeps Sector Perform Rating	Apr. 08	MT
Stephens Adjusts Bio-Techne's Price Target to $87 From $70, Keeps Overweight Rating	Feb. 02	MT
Deutsche Bank Cuts Bio-Techne Price Target to $85 From $88, Maintains Buy Rating	Feb. 02	MT
RBC Cuts Price Target on Bio-Techne to $75 From $85, Notes Revenue Growth Turned Negative, Keeps Sector Perform Rating	Feb. 02	MT
Stifel Nicolaus Downgrades Bio-Techne to Hold from Buy, $65 Price Target	Feb. 02	MT
UBS Initiates Coverage on Bio-Techne With Buy Rating, $80 Price Target	Dec. 07	MT
Deutsche Bank Cuts Bio-Techne Price Target to $70 From $100, Maintains Buy Rating	Nov. 01	MT
KeyBanc Cuts Price Target on Bio-Techne to $80 From $115, Maintains Overweight Rating	Nov. 01	MT
RBC Trims Price Target on Bio-Techne to $83 From $85, Keeps Sector Perform Rating	Nov. 01	MT
William Blair Initiates Coverage on Bio-Techne with Outperform Rating	23-08-28	MT
RBC Trims Bio-Techne's Price Target to $87 From $88, Keeps Sector Perform Rating	23-07-17	MT
RBC Trims Price Target on Bio-Techne to $88 From $90, Maintains Sector Perform Rating	23-05-15	MT
Baird Adjusts Price Target on Bio-Techne to $100 From $99, Maintains Outperform Rating	23-05-04	MT
RBC Lifts Price Target on Bio-Techne to $90 From $89 on View for Better 2024 EBITDA Margins, Keeps Sector Perform Rating	23-05-04	MT
RBC Lifts Price Target on Bio-Techne to $89 From $88, Maintains Sector Perform Rating	23-04-14	MT
RBC Lifts Price Target on Bio-Techne to $89 From $88, Maintains Sector Perform Rating	23-04-13	MT
RBC Trims Price Target on Bio-Techne to $88 From $89 After Fiscal Q2 Miss, Maintains Sector Perform Rating	23-02-06	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

77.29 USD

Average target price

83.64 USD

Spread / Average Target

+8.21%

High Price Target

95 USD

Spread / Highest target

+22.91%

Low Price Target

65 USD

Spread / Lowest Target

-15.90%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Bio-Techne Corporation

Scotiabank
Leerink Partners
UBS
Baird
RBC Capital Markets
Deutsche Bank Securities
Stephens Inc.
Stifel Nicolaus
KeyBanc Capital Markets
William Blair & Co.
SVB Securities LLC
Wells Fargo Securities
Citigroup
SVB Leerink
Argus

Ratings for Bio-Techne Corporation

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar